Document: New product information wording: extracts from PRAC recommendations on signals adopted at the 12-15 January 2026 PRAC-2026/2/9

Pyrogen and Endotoxins Testing: Questions and Answers-2026/3/18

Document: Opinion of the CVMP on the establishment of maximum residue limits: Lidocaine (EMEA/V/MRL/003649/MODF/0004)-2026/4/21

Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorporating Genome Editing-2026/6/2

Page: ICH E6 Good clinical practice - Scientific guideline-2026/7/15

Neovascular Age-Related Macular Degeneration: Developing Drugs for Treatment(Draft)-2023/02/24

国家药监局关于适用《Q9（R1）：质量风险管理》国际人用药品注册技术协调会指导原则的公告 （2023年第114号）-2023/9/5

Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act-2025/1/6

Page: Plasma master file certificates-2025/2/6

Document: Scientific advice under Article 115(5) of Regulation (EU) 2019/6 on veterinary medicinal products, regarding the list of substances essential for the treatment of equine species and for which the withdrawal period for equine species shall be six